An InFoods diagnostic-guided therapy (DGT) designed by Biomerica Inc. purposed for alleviating the Irritable Bowel Syndrome (IBS) symptoms after removing from diet has gained a new partner. Biomerica Inc. has announced that it has moved into a definitive agreement of a new partnership for its clinical trial of new InFoods DGT with the University of Texas Health Science Center at Houston to be part of its clinical trial for new InFoods DGT. University of Texas is allowed to start enrollment of patients in clinical trial.
University of Texas Health Science Center at Houston is basically a fifth medical center to join the clinical trial of DGT. Other four medical centers working as primary enrollment centers include Mayo Clinic, Houston Methodist, Beth Israel Deaconess Medical Center Inc. and the University of Michigan.
Chief of Gastroenterology, Hepatology, and Nutrition at the University of Texas Health Science Center at the Texas Medical Center, Dr. Brooks D. Cash stated, “We are excited about the potential impact this can make for IBS patients and excited to be part of the clinical trial group for InFoods® IBS. The product is novel in that it is addressing a root cause of IBS with a non-pharmaceutical therapy, yet can be combined with current pharmaceutical therapies to improve outcomes.”
Zackary Irani, Chief Executive Officer of Biomerica, commented: “IBS remains a major burden for up to 45 million people in the United States who desperately seek some form of medical advancement providing relief. We believe our approach, supported by a Scientific Advisory Board comprised of the leading minds in the IBS medical community, is differentiated by focusing on one possible root cause of IBS compared to simply treating symptoms.”
Over 45 million Americans suffer from Irritable Bowel Syndrome IBS with the symptoms associated with consumption of specific foods and a condition of illness which can cause impair physical and mental well-being.